Brief description of trial (Data source: BASEC)
Wir wollen herausfinden, ob die Messungen mit dem LSFG-Navi Gerät vertrauenswürdig sind und, wie sich der Blutfluss in Glaukom Patienten verändert.
Health conditions investigated(Data source: BASEC)
nicht zutreffend
Health conditions
(Data source: WHO)
Open Angle Glaucoma;Normal Tension Glaucoma;Healthy
Rare disease
(Data source: BASEC)
No
Intervention investigated (e.g. drug, therapy or campaign)
(Data source: BASEC)
Blutfluss der Netzhaut
Interventions
(Data source: WHO)
Diagnostic Test: LASER SPECKLE FLOWGRAPHY
Criteria for participation in trial
(Data source: BASEC)
Personen mit oder ohne Glaukom
Unterschriebene Einwilligungserklärung
Alter >= 18 Jahre
Exclusion criteria
(Data source: BASEC)
Minderjährige Personen
Nicht unterschriebene Einverständniserklärung
Unfähigkeit den Studienablauf zu verstehen, z. B., aufgrund von Sprachschwierigkeiten, psychische Störung, etc.
Inclusion/Exclusion Criteria
(Data source: WHO)
Inclusion Criteria:
- signed Patient Informed Consent form
- Be at least 18 years old
- Diagnosis of primary or secondary open-angle glaucoma or normal tension glaucoma or
healthy controls
Exclusion Criteria:
- Age < 18 years
- Inability to follow the procedures of the study, e.g. due to language problems,
psychological disorders, dementia, etc. of the participant.
- No vulnerable participants will be included in this study.
-
Further information on trial
Date trial registered
Jul 3, 2019
Incorporation of the first participant
Jul 1, 2019
Recruitment status
Recruiting
Academic title
(Data source: WHO)
Prospective, Non-randomised, Non-controlled Study of Reproducibility of Blood Flowmetry in Human Retina Using the Nidek Laser Speckle Flowgraphy LSFG-NAVI System
Type of trial
(Data source: WHO)
Observational
Phase
(Data source: WHO)
N/A
Primary end point
(Data source: WHO)
Coefficients of variation (COV);intraclass correlation coefficients (ICCs)
Secundary end point
(Data source: WHO)
Cofounde
Contact information
(Data source: WHO)
Please refer to primary and secondary sponsors
Trial results
(Data source: WHO)
Results summary
no information available yet
Link to the results in the primary register
no information available yet
Information on the availability of individual participant data
no information available yet
Trial sites
Trial sites in Switzerland
(Data source: BASEC)
Aarau, Zurich
Countries
(Data source: WHO)
Switzerland
Contact for further information on the trial
Details of contact in Switzerland
(Data source: BASEC)
PD Dr. med. Marc Töteberg-Harms
+41 44 255 87 94
marc.toeteberg@usz.ch
Contact for general information
(Data source: WHO)
Marc Töteberg-Harms, MD, FEBO
UniversityHospital Zurich, Department of Ophthalmology, Zurich, Switzerland
+41442558794
marc.toeteberg@usz.ch
Contact for scientific information
(Data source: WHO)
Marc Töteberg-Harms, MD, FEBO
UniversityHospital Zurich, Department of Ophthalmology, Zurich, Switzerland
+41442558794
marc.toeteberg@usz.ch
Authorisation by the ethics committee (Data source: BASEC)
Name of the authorising ethics committee (for multicentre studies only the lead committee)
Kantonale
Ethikkommission Zürich
Date of authorisation by the ethics committee
17.06.2019
Further trial identification numbers
Trial identification number of the ethics committee (BASEC-ID)
(Data source: BASEC)
2019-00098
Secondary ID (Data source: WHO)
LSFG Repro
Back to overview
